Oxford Biomedica Signs Licence and Supply Agreement with Cabaletta Bio for LentiVector® Platform
Oxford, UK – 5 January 2022: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia, USA-based clinical-stage biotechnology company… Read More